A new approach on bullous pemphigoid therapy

被引：24

作者：

Saouli, Z. ^{[1
]}

Papadopoulos, A. ^{[1
]}

Kaiafa, G. ^{[1
]}

Girtovitis, F. ^{[1
]}

Kontoninas, Z. ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, AHEPA Hosp, Propedeut Clin Internal Med, Thessaloniki, Greece

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷 / 04期

关键词：

D O I：

10.1093/annonc/mdn046

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：825 / 826

页数：2

共 5 条

[1] CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 [J].

Golay, J ;

Lazzari, M ;

Facchinetti, V ;

Bernasconi, S ;

Borleri, G ;

Barbui, T ;

Rambaldi, A ;

Introna, M .

BLOOD, 2001, 98 (12) :3383-3389

[2] Management of bullous pemphigoid - Recommendations for immunomodulatory treatments [J].

Kirtschig, G ;

Khumalo, NP .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2004, 5 (05) :319-326

[3]

Korman NJ, 2002, NEW ENGL J MED, V347, P143

[4]

PASCAL J, 2005, ARCH DERMATOL, V141, P691

[5] Case report - Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease [J].

Szabolcs, P ;

Reese, M ;

Yancey, KB ;

Hall, RP ;

Kurtzberg, J .

BONE MARROW TRANSPLANTATION, 2002, 30 (05) :327-329

← 1 →